The research firm Contrive Datum Insights has just recently added to its database a report with the heading global HIV Drugs Market .Both primary and secondary research methodologies have been utilised in order to conduct an analysis of the worldwide HIV Drugs Market . In order to provide a comprehensive comprehension of the topic at hand, it has been summed up using appropriate and accurate market insights. According to Contrive Datum Insights, this worldwide comprehensive report is broken up into several categories in order to present the data in a way that is understandable, succinct,

1. Contrive Datum Insights
Global Research And Consulting
A complete solution to explore all the potential aspect to
drive the growth of the business industries.

2. v
ABOUT US
Contrive Datum Insights (CDI) is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers. CDI’s experienced
team of Analysts, Researchers, and Consultants uses proprietary data sources and various
tools and techniques to gather, and analyse information. Our business offerings represent the
latest and the most reliable information indispensable for businesses to sustain a competitive
edge.
Each CDI syndicated research report covers a different sector — such as chemicals, materials,
metals & mining, pharmaceuticals, energy, automotive, food and beverages, semiconductors,
med-devices, consumer goods and information technology. These reports provide in-depth
analysis and deep segmentation to possible micro levels. With wider scope and stratified
research methodology, our syndicated reports strive to serve the overall research requirement
of clients.

3. v
Services Offered :
 Market Intelligence & Market Opportunity
Assessment
 Market Size & Segmentation
 Market Entry Strategy
 Competitor Benchmarking
 Pricing Intelligence
 Customer Intelligence
 Sourcing Intelligence
 New-Generation Products & Technologies
 Distribution & Sales Channel Assessment

4. v
CLIENTELE:
Some of the global leading clients that we have served:

5. v
CLIENTELE:
Some of the global leading clients that we have served:

6. v
At a CAGR of 3.8% between 2020 and 2027, the global HIV drugs market is projected to grow from its
2019 valuation of USD 30.89 billion to USD 34.54 billion by 2022 and USD 46.55 billion by 2030.One of
the most serious and long-lasting diseases is AIDS, caused by the human immunodeficiency virus.
Infected blood, sperm, breast milk, or other bodily fluids can spread the virus that causes AIDS. The
World Health Organization (WHO) estimates that by 2020, 37.1 million people around the world would
be living with HIV infection. An estimated 34,800 new cases of HIV were diagnosed in the United States
year 2019. The number of new HIV infections has dropped by 8%, from 37,800 in 2015 to 34,800 in 2019,
following a period of stability. A total of 36,801 people in the United States and six of its dependent
territories were newly diagnosed with HIV in 2019, a decrease of 9% from 2015. The spread of HIV
testing is not uniform from state to state or area to region.Recent years have seen consistent growth in
the global HIV medications market due to rising rates of HIV/AIDS diagnosis and treatment
advancements. Antiretroviral therapy (ART) has helped to extend the lives of millions of individuals living
Market Overview

7. v
By Region:
Markets for HIV medications around the world have been broken down by geography to look at trends in places
including North America, Latin America, the Middle East, Asia-Pacific, Africa, Europe, and India. In the near future, the
HIV Drugs market is expected to be led by the global region. The worldwide industry is divided into four sections based
on geography: North America, Europe, Asia-Pacific, and RoW. By 2020, the North American market is projected to be
worth USD 20.27 billion, making it a key region in the forecast. The spread of HIV in the United States is partly
attributable to the region's impact. About 1.2 million people were living with HIV as of the end of 2018, according to a
report by the CDC in 2021. With such a large pool of potential buyers, the price of HIV medication is sure to rise. The
education and awareness of the local populace also contribute to the development of the area. The presence of major
players providing novel HIV medications for the treatment of HIV infection is also expected to boost the expansion of
the market.Due to rising rates of HIV infection and the concentration of HIV medicine manufacturers in Europe, that
area is projected to become the second largest market throughout the projection period. Furthermore, expanding
strategic alliances among European enterprises will increase medicine supply, hence bolstering market development in
Europe. An illustration of this is the July 2020 partnership between Theratechnologies Europe Limited, a European
subsidiary of Theratechnologies Inc., and Loxxess for the distribution of the antiviral medication Trogarzo across

8. v
The Global HIV Drugs Market has been segmented into:
By Type:
• Multi-Class Combination Products
• Nucleoside Reverse Transcriptase Inhibitors
• Non-Nucleoside Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Fusion Inhibitors
• Entry Inhibitors - CCR5 Co-Receptor Antagonist
• HIV Integrase Strand Transfer Inhibitor
By Application
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. v
The Global HIV Drugs Market has been segmented into:
By Region
North America
• US
• Canada
• Mexico
• Rest of North America
The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
•Latin America
• Brazil
• Argentina
• Rest of Latin America
By Region
Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
By Region
Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe

10. v
• In January 2021, the U.S. Food and medication Administration (FDA) gave ViiV Healthcare approval to
sell Cabenuva, the first and only full long-lasting regimen combo medication for HIV therapy.U.S. Food
and Drug Administration (FDA) approval for the combination medications PIFELTRO and DELSTRIGO was
granted to Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., in September 2019. HIV-1
infected adults may benefit from these medications.
• Efavirenz tablets were first made available in the United States by Mylan Inc. in February 2018. The
first available alternative to Sustiva is the pill form of efavirenz. Treatment of HIV-1 infection, both in
adults and children, requires the use of many antiretroviral drugs.
• The FDA granted approval for Juluca in the United States to ViiV Healthcare in November 2017. The
viral infection can be suppressed with just one dosage of Juluca, an antiretroviral therapy (ART)
regimen.According to a press release from Unitaid and Clinton Health Access Initiative Inc
Strategic Development:

11. v
• Merck & Dohme Corp. (Kenilworth, France)
• Gilead Science, Inc. (Foster city, USA)
• Janssen Pharmaceutical Inc. (Johnson and Johnson, Belgium)
• ViiV Healthcare (Research Triangle Park, U.S)
• Bristol-Myers Squibb Company (New York city, U.S)
• Mylan Pharmaceuticals (Canonsburg USA)
• Genentech (South San Francisco, USA)
• GlaxoSmithKline plc. (Brentford, U.K)
MARKET PLAYERS

12. v
Customer Experiences
“Very happy with the service. Report quality as well as response time
for my custom market study was great. I am looking forward to work
with Contrive Datum Insights (CDI) in future. “
G. Luca, A+ Outsourced Marketing
“We are satisfied with research report offered by Contrive Datum
Insights (CDI) .” We appreciate your support throughout the project.”
Consulting Company (privacy requested)
"You and your team did a terrific job on this project.” CDI will be at the
top of our list in the future for market research projects.”
Europe based Fortune 500 Company (privacy requested)

13. v
Benefits of
Association
By associating with Contrive Datum Insights (CDI) , customer can enjoy following
benefits:
 One-Stop-Destination for all research needs (Syndicate and Custom Reports)
 Reduced Budget and Faster Turnaround Time
 Focused Research Team - Contrive Datum Insights (CDI) can arrange a dedicated team of
2-3 resources with 1 Research Manager , who will look after any ad-hoc needs of the client
 Dedicated Account Manager
 24/7 availability for any custom needs of the client
 Flexible Partnering Model to accommodate client’s research needs
 Access to Data-Cuts related to required Market for global region
 ▪ Industry Update on Weekly/Bi-Weekly/Monthly basis
 ▪ Market Trend Analysis on Monthly/Quarterly basis

14. v
To know more about us, please visit our website:
www.contrivedatuminsights.com
For sales queries or new topics email us on:
anna@contrivedatuminsights.com
Thank You!